Allergy vaccine market to witness significant growth due to increased knowledge of allergies, rising allergy incidence, limited symptomatic treatment efficacy, long-term relief desire, managing pediatric allergies.

Market Research Future (MRFR) has published a cooked research report on the “Global Allergy vaccine Market” that contains information from 2018 to 2032. The Allergy vaccine market is estimated to register a CAGR of 9.7% during the forecast period of 2023 to 2032.

Market Highlights

The global allergy vaccine market is accounted to register a CAGR of 7.9% during the forecast period and is estimated to reach USD 3.82 Billion by 2032.

The allergy vaccine market was driven by factors such as the increasing prevalence of allergies, the demand for more effective and long-lasting treatments, and advancements in medical research and technology. The market was primarily dominated by a few key players and was characterized by ongoing research and development efforts to create more targeted and efficient allergy vaccines.

Key Players

MRFR recognizes the following companies as the key players in the global Allergy vaccine market— ALK (Denmark), Stallergenes Greer (Switzerland), Allergy Therapeutics (U.K.), HAL Allergy B.V. (Netherlands), HollisterStier Allergy (U.S.), Zhejiang Wolwo Bio-pharmaceutical Co., Ltd (China), LETIPharma (Spain), Dermapharm Holding SE (Germany) and others

Segment Analysis

The global Allergy vaccine market has been segmented based type, application and distribution channel.

On the basis of type, the market is segmented into subcutaneous immunotherapy and sublingual immunotherapy. The subcutaneous immunotherapy segment dominated the market in 2022. This is so that allergies to pollen, dust mites, and insect stings can be treated with SCIT, which is the most efficient type of allergy vaccination therapy.

Based on application, the global allergy vaccine market has been segmented into allergic rhinitis, allergic asthma and others. The allergic rhinitis segment dominated the market in 2022. This is due to allergic rhinitis, the most common type of allergy, which affects an estimated 10% of people globally.

Based on distribution channel, the global allergy vaccine market has been segmented into hospital pharmacies, retail pharmacies & online pharmacies. The hospital pharmacies category generated the most income in 2022. This is because the majority of allergy injections are purchased from hospital pharmacies.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Allergy vaccine market Research Report

Regional Analysis

The global Allergy vaccine market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Allergy vaccine market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Allergy vaccine market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Allergy vaccine market comprises of Middle East, Africa, and Latin America.

The North America allergy vaccine market dominated this market in 2022 (45.80%). There is a good network of hospitals and medical facilities in the region, as well as laboratories and specialists in allergy and immunology among the medical staff. Modern therapies like allergy shots, as well as allergy testing and therapy, are made more accessible by this infrastructure.

Moreover, the Europe market has been persistently growing over the forecast period. Allergy-related illnesses such allergic rhinitis, asthma, and food allergies are become much more common in Europe. Due to the significant frequency of allergies, there is a growing demand for long-lasting and effective treatment options, which is what is driving the development of allergy vaccinations.

Additionally, Asia Pacific is anticipated to experience the quickest growth over the forecast period. Urbanization and industrialisation have increased exposure to air pollution and environmental allergens in several parts of the Asia Pacific region. Because allergic issues are increasingly widespread and people are more aware of how these things affect their health, there is a greater interest in novel therapeutic options.

Furthermore, the rest of the world's allergy vaccine market is divided into the Middle East, Africa, and Latin America. The Latin America allergy vaccine market's dynamics are influenced by varying allergy prevalence, healthcare infrastructure, regulations, and economic factors across countries. Patient awareness, research efforts, and the presence of key players impact the adoption of allergy vaccines. Up-to-date market reports provide insights into trends, growth factors, and regional developments.

Key Findings of the Study

• The global allergy vaccine market is expected to reach USD 3.82 Billion by 2032, at a CAGR of 7.9% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to urbanization and industrialization have increased exposure to air pollution and environmental allergies.


• Based on distribution channel, the hospital pharmacies segment was attributed to holding the largest market in 2022.


• ALK (Denmark), Stallergenes Greer (Switzerland), Allergy Therapeutics (U.K.), HAL Allergy B.V. (Netherlands), HollisterStier Allergy (U.S.), Zhejiang Wolwo Bio-pharmaceutical Co., Ltd (China), LETIPharma (Spain), Dermapharm Holding SE (Germany) and others